Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of the National Cancer Institute|February 4, 2016
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO StudyDavid Tougeron, Guillaume Mouillet, Isabelle Trouilloud, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studyJeannie M'Baloula, David Tougeron, Alice Boilève, et al.
Clinical Colorectal Cancer|August 2, 2020
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)Emmanuelle Samalin, Christelle de la Fouchardière, Simon Thézenas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trialDavid Malka, Eric François, Frédérique Penault-Llorca, et al.
Nature Communications|August 13, 2025
FedECA: federated external control arms for causal inference with time-to-event data in distributed settingsJean Ogier du Terrail, Quentin Klopfenstein, Honghao Li, et al.
The Journal of Clinical Investigation|August 3, 2004
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsChristophe Borg, Magali Terme, Julien Taïeb, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
Pageof 5